Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Pipeline Review, H2 2016’, provides in depth analysis on Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Clinuvel Pharmaceuticals Limited

Mallinckrodt Plc

Palatin Technologies, Inc.

Retrophin Inc.

SolaranRx, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Overview 6

Therapeutics Development 7

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Products under Development by Stage of Development 7

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Products under Development by Therapy Area 8

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Products under Development by Indication 9

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Products under Development by Companies 12

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development 21

Clinuvel Pharmaceuticals Limited 21

Mallinckrodt Plc 22

Palatin Technologies, Inc. 23

Retrophin Inc. 24

SolaranRx, Inc. 25

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles 26

afamelanotide - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AQB-565 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

corticotropin - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

cosyntropin - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CUV-9900 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PL-8176 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

PL-8177 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SRX-1177 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

VLRX-001 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Projects 43

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products 44

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Featured News & Press Releases 45

Aug 03, 2016: Clinuvel prepares New Drug Application for the treatment of erythropoietic protoporphyria 45

Jul 18, 2016: FDA accepts SCENESSE clinical data package for NDA submission 46

Jul 06, 2016: FDA awards SCENESSE Fast Track designation for treatment of EPP 48

Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 49

Jun 22, 2016: Clinuvel’s SCENESSE launched in Europe 50

Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 50

May 26, 2016: Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property 52

May 18, 2016: German Porphyria Expert Centres to start distribution of SCENESSE (afamelanotide 16mg) 53

May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 53

Mar 24, 2016: NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria 54

Feb 16, 2016: Clinuvel brief on European commercialisation 55

Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias 55

Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 56

Dec 03, 2015: Update on North American vitiligo program for SCENESSE 58

Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Clinuvel Pharmaceuticals Limited, H2 2016 21

Pipeline by Mallinckrodt Plc, H2 2016 22

Pipeline by Palatin Technologies, Inc., H2 2016 23

Pipeline by Retrophin Inc., H2 2016 24

Pipeline by SolaranRx, Inc., H2 2016 25

Dormant Projects, H2 2016 43

Discontinued Products, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports